DrugOn: a fully integrated pharmacophore modeling and structure optimization toolkit

Dimitrios Vlachakis, Paraskevas Fakourelis, Christos Makris, Sophia Kossida

During the past years pharmacophore modeling has become one of the key components in computer-aided drug design and generally in modern drug discovery. DrugOn is a fully interactive pipeline designed to exploit the advantages of modern programming and overcome the command line barrier with two friendly environments for the user (either novice or experienced in the field of Computer Aided Drug Design) to perform pharmacophore modeling through an efficient combination of the PharmACOphore, Gromacs, Ligbuilder and PDB2PQR suites. Our platform features a novel workflow that guides the user through each logical step of the iterative 3D structural optimization setup and drug design process. For the pharmacophore modeling we are focusing on either the characteristics of the receptor or the full molecular system, including a set of selected ligands. DrugOn can be freely downloaded from our dedicated server system at www.bioacademy.gr/bioinformatics/drugon/

DrugOn: a fully integrated pharmacophore modeling and structure optimization toolkit

Dimitrios Vlachakis[1,2,#,*], Paraskevas Fakourelis[1,2,#], Christos Makris[2] and Sophia Kossida[1,3*]

[1] Bioinformatics & Medical Informatics Team, Biomedical Research Foundation, Academy of Athens, Athens, Greece,
[2] Computer Engineering and Informatics Department, University of Patras, Patras, Greece.
[3] IMGT, Laboratoire d'ImmunoGénétique Moléculaire, Institut de Génétique Humaine, Montpellier, France.

[#] Equally contributing authors
[*] Corresponding authors: dvlachakis@bioacademy.gr, skossida@bioacademy.gr

ABSTRACT

During the past years pharmacophore modeling has become one of the key components in computer-aided drug design and generally in modern drug discovery. DrugOn is a fully interactive pipeline designed to exploit the advantages of modern programming and overcome the command line barrier with two friendly environments for the user (either novice or experienced in the field of Computer Aided Drug Design) to perform pharmacophore modeling through an efficient combination of the PharmACOphore, Gromacs, Ligbuilder and PDB2PQR suites. Our platform features a novel workflow that guides the user through each logical step of the iterative 3D structural optimization setup and drug design process. For the pharmacophore modeling we are focusing on either the characteristics of the receptor or the full molecular system, including a set of selected ligands. DrugOn can be freely downloaded from our dedicated server system at www.bioacademy.gr/bioinformatics/drugon/

INTRODUCTION

Fully automated methods of pharmacophore model design can help facilitate the process of modern computer based drug discovery (Chen et al. 2013; Wallach & Lilien 2009). Computers gain credibility in the field of computational biology and drug design, as new more efficient algorithms and pipelines are established (Donsky & Wolfson 2011; Loukatou et al. 2014; Ortuso et al. 2006).
The idea of pharmacophore was first defined by Paul Ehrlich as 'a molecular framework that carries (phoros) the essential features responsible for a drug's (pharmacon) biological activity' back in 1909 (Ehrlich 1909; Guner 2000). According to the recent definition by IUPAC, a pharmacophore model is 'an ensemble of steric and electronic features that is necessary to ensure the

optimal supramolecular interactions with a specific biological target and to trigger or block its biological response (Wermuth 1998).

With computer-aided drug design being an integral part of the drug discovery and lead optimization process, pharmacophore models have become a key component in understanding the receptor-ligand interactions. Specifically, pharmacophore models have contributed in evolving the drug design process by shifting the focus from 2-dimensional atoms connectivity to 3-dimensional chemical features arrangement (Faulon et al. 2008; Guner 2002; Balatsos et al. 2012; Dalkas et al. 2013) where the features might be hydrophobic or hydrophilic regions, specific atoms, centers of aromatic or not aromatic rings, positive or negative charges and hydrogen bond donors or acceptors (Pires et al. 2014; Zhang et al. 2005). The 3D pharmacophore modeling methods take into consideration the 3-dimensional structures and binding of receptors and inhibitors, in order to identify areas that are favorable or unfavorable to a specific receptor-inhibitor interaction (Vlachakis et al. 2012b; Vlachakis & Kossida 2013). Pharmacophore models contribute to drug discovery by providing a number of benefits, such as the fact that they represent chemical function, valid for the existing bounds as well as for unknown agents. In addition, they are computationally efficient due to their simplicity, which makes them suitable for large scale high throughput virtual screening (Floris et al. 2011; Frommel et al. 2003; Vlachakis et al. 2013a; Vlachakis et al. 2013b). Finally they are comprehensive and editable, so the information can be easily traced back by adding or omitting chemical feature constraints. A pharmacophore model can be expressed in two ways, firstly in a ligand-based approach and secondly in a structure-based approach (Yang 2010). A major goal in drug design is to increase potency by optimizing interactions such us the binding of a ligand to its pharmacological target, that requires complementarity of both bonding partners in terms of shape and electrostatics (Korb et al. 2010). Pharmacophore models have been already used in a variety of projects in order to exploit their benefits in high throughput virtual screening (Fei et al. 2013; Niu et al. 2013; Suresh & Vasanthi 2010; Vlachakis et al. 2013c; Vlachakis et al. 2014). Pharamcophore models have been successfully used for the identification of human chymase inhibitors (Arooj et al. 2013) and for the efficient of overlay of drug-like organic molecules (Wolber et al. 2006). The benefits of pharmacophore modeling at computer-aided drug design resulted in the development of a variety of automated tools and applications during the past 20 years (Vlachakis et al. 2013d; Vlachakis et al. 2013e; Vlachakis et al. 2013g). However the pharmacophore modeling approaches have not reached yet their full potential, as they are limited by a number of obstacles, which are dictated by the ongoing demand for reducing todays very high cost of drug design and drug discovery (Yang 2010; Vlachakis et al. 2013h; Vlachakis et al. 2013i).

Herein, we introduce DrugOn, a free, open source, unix-based software package for pharmacophore modeling. DrugOn is an interactive platform combining the algorithms of PDB2PQR v.1.8 (Dolinsky et al. 2007; Dolinsky et al. 2004), Ligbuilder v.1.2 and v.2.0 (Wang et al. 2000; Yuan et al. 2011), Gromacs v.4.5.5 (Pronk et al. 2013) and pharmACOphore (Korb et al. 2010) in

a seamless rational pipeline developed in Perl/Tcl-Tk. All previously mentioned suites remain a set of numerous modules, lacking an object-oriented graphical user interface (GUI) to facilitate their use. DrugOn was developed to smoothen and automate the tedious tasks of pharmacophore modeling and 3D structure optimization. In order to provide the user with a 3D molecular viewer, whose usage is a focal point in modern drug discovery and in computer-aided drug design, we also incorporated the Pymol suite ([DeLano 2002](#)). The DrugOn idea is to provide a scientifically sound pharmacophore design suite, which remains easy to comprehend and work with. As a result DrugOn's audience includes both the inexperienced, novice student to the highly demanding researcher and expert in the field of computer-aided drug design. So, by developing a basic interface for novice users we provide them with an automated platform that will enable them to learn by making easy experiments and to practice in computer-aided drug design by utilizing their ideas and overcoming their lack of experience. On the other hand DrugOn Pro has a fully integrated interface with all the parameterization an expert needs. More specifically DrugOn addresses all common problems associated with PDB file formatting and partial charges. Subsequently, the receptor is structurally optimized by energy minimization using a variety of different force fields as implemented into Gromacs. After structural optimization, the Ligbuilder suite is used to generate novel molecules for the given site or to improve an existing family lead or set of compounds. Finally, the pharmACOphore program is used for the pairing of ligands, resulting in the construction of a 3D pharmacophore model.

PIPELINE'S METHODS AND DESCRIPTION

With a universal installation procedure the DrugOn suite provides the user with two interfaces to choose from. DrugOn Pro is intended for more experienced users while the basic, abstract version of DrugOn is intended for inexperienced novice users. A comprehensive flowchart of the DrugOn pipeline can be found in Figure S1.

DrugOn

In the main window of DrugOn, the tab layout changes into a frame layout at the left of the main window with two buttons "next" and "previous" (Fig. 1) in order to make the step-by-step process more efficient and the layout smoother for the novice users. It also provides the user with a process log window, at the right of the main window for the real time calculations that take place in the background, with one vertical and one horizontal scroll bars, thus making the information that the user provided easier to traced back. In the DrugOn pipeline, the process for a pharmacophore modeling experiment is broken down to four steps:

(1)Input preparation.
This is the first and very essential step, which is missing from a lot of major suites, where the input (PDB) files are automatically checked and repaired so that all compatibility issues are addressed and basic chemical information is calculated before the experiment. In addition, the missing

134   hydrogens are added and partial charges are calculated.

135   However, in order to make the process easier for the novice users, the
136   choices to remove heteroatoms, for the force field, and to neutralize or not
137   the C' and N' termini of the protein have been selected by default.
138   Therefore, the responsibility of the user is only to choose the input PDB
139   file, as well as the name and the path of the output PDB file. The above
140   options are processed with the PDB2PQR (Dolinsky et al. 2007; Dolinsky et
141   al. 2004) algorithm.

142 *(2) Receptor optimization.*

143 A major problem when removing heteratoms or ligands (Input preparation)
144   from PDB files is that the receptor structure remains in its bound
145   conformation, unless it is structurally optimized. In this second automated
146   step the user can benefit from the conformational optimization of the
147   receptor. An issue that is a major drawback of many structure-based drug
148   designing algorithms. Many inconsistencies and free energy issues that
149   may result from the removal of heteratoms, without bringing it back to the
150   relaxed conformation of the PDB receptor file are addressed. So by using
151   the versatile Gromacs (Pronk et al. 2013) suite, the receptor is
152   conformationally optimized via energy minimization before the
153   experiment. Also in this step, the available choices for the user are the
154   input PDB file, the name and the path of the output PDB file.

155 *(3) Ligand building.*

156   At this stage, the actual structure-based drug design of the new ligand
157   structures takes place. This step enables the user to fully parameterize the
158   ligand-building process, with the use of Ligbuilder v.1.2 (Wang et al.
159   2000). The user has just to define the active or pocket of interest by
160   positioning a 'seed' chemical structure in it. Then the algorithm will
161   proceed with either the growing of the seed to a drug-like compound,
162   using the predefined criteria in the parameters window or the linking
163   approach (for multiple seeds). Finally the drug candidates that do not
164   comply with the user's criteria will be screened out, by applying a
165   similarity cutoff filter, that is user configurable.

166 (4) *Pharmacophore.*

167   The final step of the DrugOn pipeline is the automatic structure alignment
168   of the molecules that were produced in the previous steps. At this point,
169   the similarity-based scoring function tuned for ligand-based pose
170   prediction is combined with a hybrid ant colony optimization algorithm via
171   pharmACOphore (Korb et al. 2010). The scoring function combines an
172   intraligand potential with the distance-dependent potential. The
173   description of molecular similarity is based on hydrogen bond donors and
174   acceptors as well as ring systems and other pharmacophoric features. The
175   identification of corresponding pharmacophoric features in this method
176   depends on the accuracy of the scoring function. Therefore, a fully
177   parameterized configuration file has been created in order to serve the
178   pharmacophore modeling experiments.

Toolkits description

Furthermore, in DrugOn's interface, a manual for the use of DrugOn is provided using the stystem's default web browser through the help button. Options such as print, clear, save and load all output files are provided to the user in order to print or save for further analysis, trace errors, as well as load previous experiments. Finally there is an option to clear the output of the log process window in order to start a completely new experiment without any trace of previous outputs that have no longer any use and might be confusing and time-consuming for the user to manually edit. All those options that were introduced earlier have keyboard shortcuts that can be found at the File button on the window's top left corner, for faster and more ergonomic use. Additionally, a button for opening a new terminal is available in case the user needs two or more terminals for other uses (besides DrugOn) when an experiment takes place, as the terminal from which the DrugOn was launched is occupied until the user exits DrugOn. With the handle databases button the user can view and edit molecule databases from the window that pops up. The format that is supported is based on the one used by Ligbuilder to manage fragment and molecular databases. Every database is a folder consisting of the included molecule files in .mol2 format and an INDEX text file which lists the molecular parameters alongside extra information and properties bound to each molecular entry. Also there is a preferences button, through which the user can handle some of the DrugOn settings, like module path settings and the system's local folder management. By default the software paths and installation sites are user defined at the DrugOn automated setup. Another frame in the preferences window contains the default parameter files, where the user can set the default parameter file that will be used for any given experiments. These files are stored/saved and can be re-used as recipe files to re-run similar experiments by just altering the input files. Moreover, an experiment preparation log is saved in the form of a lab-book with the experimental parameters that are of importance to pharmacophore design, next to a recording of the input files, the date and the computer used to run the simulation. This way, troubleshooting becomes easy when things go wrong and the chances of finding what went wrong increase dramatically. Moreover in the preferences window the user has the option to choose the preferred applications, for the text editor, terminal molecular viewer and xvg graph viewer. Additionally, DrugOn's pipeline is capable of starting a log file from the preferences menu where the user predefines. DrugOn will automatically save all output results from the experiments that take place in the form of plain text file format for future reference. This option is essential for keeping track of all useful information that is complicated and takes a lot of time for some users. These files are pre-formatted and ready to print, email or convert into PDF format. Notably, the status tray area provides the user with 2 progress indicators, a progress bar and a percentage (%) of the completed work. A processor's, memory and swap file usage gauge is to be found right next to the logging indicator, providing real time information of systems resources.

225   DrugOn Pro

226   DrugOn Pro is a more comprehensive, in depth approach aimed to the more
227   expert and professional users. DrugOn's Pro main window is a menu interface
228   with a tab step-by-step layout (Fig. 2). It also provides the user with a process
229   log window, at the bottom of the main window for the real time calculations
230   that take place in the background, with one vertical and one horizontal scroll
231   in order to make the information that the user provided easily traced back.
232   At the DrugOn Pro interface for a pharmacophore modeling experiment the
233   process is separated in the four same steps as DrugOn with some difference
234   most likely in parameterization:

235   *(1) Input preparation.*
236   Where the user has the benefit to fully parameterize the pdb input file
237   with choices such us: removing heteroatoms, choosing the force field, and
238   choosing whether to neutralize or not the C' and N' termini of the protein.
239   The above options are processed with the PDB2PQR (Dolinsky et al. 2007;
240   Dolinsky et al. 2004) algorithm.
241   *(2) Receptor optimization.*
242   The second step of DrugOn Pro remains the same with DrugOn only that
243   here the user has the choice to either use the default parameters or fully
244   customize the parameters for the experiment. The parameters in this step
245   are: the force field that Gromacs uses (Force Field), the type of periodic
246   box that surrounds the protein (Box Type), the distance parameter that
247   decides the size of the box where dynamics will take place (Sol-Box
248   Distance), the choice to perform energy minimization in the presence or
249   absence of water (Solvate Protein in Water), the water model that is used
250   for water molecules (Water Model), the option to remove the overall
251   charge from the system (Neutralize system), the option to remove or leave
252   the water or ions in the output PDB File (Remove water/ions from output
253   PDB File), the option to show a graph of the protein's potential energy
254   MDRun (Show resulting Energy Graph) and to path the parameter file
255   needed for energy minimization (Parameter File) available for the user.
256   *(3) Build ligands.*
257   At this stage, the actual structure-based drug design of the new ligand
258   structures takes place. DrugOn Pro enables the user to fully parameterize
259   the ligand-building process, with the use of ont only Ligbuilder v.1.2 but
260   also Ligbuilder v.2.0 (Wang et al. 2000; Yuan et al. 2011).

261   • Ligbuilder v.1.2:

262   The use of Ligbuilder v.1.2 stays the same as DrugOn, So the user still
263   has the options of pocket, grow, link and process but also has the
264   option of Ligbuilder v.2.0.
265   • Ligbuilder v.2.0:
266   When using Ligbuilder 2.0 the cavity is automatically detected. In the
267   case of many potential active sites the user will be asked to choose

268   one. The parameters set in the Parameter and Index files are used to
269   start the drug design process. So at this step the process is organized
270   in three fully user-customizable phases. First it prepares and
271   summarizes the 3D properties of the scaffolding, common core
272   structures that later will be generated and analyzed. Then the user has
273   to choose between the growing and linking algorithms of Ligbuilder, as
274   soon as the user has completed the parameters setup section and then
275   the combination of molecular fragments starts automatically. Finally the
276   elite molecules are selected for the next step, in the compound
277   screening function.
278 *(4) Pharmacophore.*
279   At the final step, because the identification of corresponding
280   pharmacophoric features in pharmACOphores method counts on the
281   accuracy of the scoring function the DrugOn Pro benefits the users
282   pharmacophore modeling experiments with two more options. So, the user
283   has the choice of a fully parameterized configuration file that
284   pharmACOphore uses (the default that DrugOn). Moreover the user is
285   provided with the option to create/edit his own configuration file with the
286   parameters that are needed for each experiment.

287 A major issue with most major drug design/pharmacophore suites is the
288 installation process on UNIX/Linux based systems, as the command line is not
289 very popular to the majority of the pc users. That is especially true for people
290 that use only graphically enabled operating systems and avoid using every
291 application or software package that runs on linux because of its difficulty
292 when graphical interface is not an option. The DrugOn is a pipielined software
293 package based on Linux-ubuntu systems, that has been specifically designed
294 to provide the user with a seamless setup via a graphical interface that
295 simplifies the installation of DrugOn.

296 VALIDATION

297 DrugOn is not the first platform designed for pharmacophore modeling. A
298 similar pipeline approach for a complete drug design toolkit (not
299 pharmacophore) has been published by (Vlachakis et al. 2013f) with the
300 Drugster toolkit. Moreover, a series of different approaches have been made
301 the past years which resulted in some commercially available suits like MOE
302 (MOE 2010), or some free available suits like pharmer (Koes & Camacho
303 2011) and open3dqsar (Tosco & Balle 2011), two really good and efficient
304 software packages that have been developed. Schrödinger has also
305 developed Phase, which is also distributed as a commercial module of the
306 Maestro suite (Dixon et al. 2006a; Dixon et al. 2006b).
307 In an effort to quantitatively and qualitatively evaluate the performance of
308 DrugOn we used two different and quite diverge use cases. First use case was
309 the crystal structure of the chimeric protein of 5-HT1B-BRIL, pdb entry: 4IAR

310 (Figure S2) and secondly the case of the pharmacophore design for PARN
311 (Figure S3) (Vlachakis et al. 2012a). As benchmark control we compared
312 DrugOn firstly to the rather expensive and commercially available package
313 MOE and its build-in modules (breed) and secondly to the Schrödinger suite
314 and its built-in pharmacophore module named Phase. The results have been
315 summarized in figures S2 and S3. It is clear that in both cases the DrugOn
316 suite performed as good as the other rather expensive rival commercial
317 suites. The number, structure and 3D alignment of candidate compounds and
318 3D pharmacophore model design as it was produced by DrugOn is almost
319 identical to that of MOE and similar to Phase. As far as accuracy and
320 reliability goes, we are now confident that DrugOn reported a set of
321 pharamcophore models that has been evaluated and confirmed by *in vitro*
322 assays, as the predicted poly-A-DNP was found active in the sub-milimolar
323 range (Vlachakis et al. 2012a)

324 **CONCLUSION**

325 The DrugOn has been developed with the aim to pipeline some of the major
326 drug design suites in an effort to create reliable 3D pharmacophore models. It
327 stands out from its competition as it seamlessly combines the results of state
328 of the art algorithms and suites, which are just difficult to combine and install
329 or run individually, whilst remaining distributed as freeware. Operation
330 manuals, tutorials on various use cases, quick guides for teaching purposes
331 as well as multimedia/video installation guidelines and scientific support for
332 DrugOn is provided via our dedicated webserver at:
333 http://www.bioacademy.gr/bioinformatics/drugon/.

334 **Figure Legends:**
335 **Figure 1.** The main window of the DrugOn platform.

336 **Figure 2.** The main window of the DrugOn Pro platform.

337 **Figure S1.** A flowchart of the DrugOn pipeline.

338 **Figure S2.** The 5-HT1B-BRIL use case benchmark of DrugOn. Here is the 3D
339 alignment of the qualifying molecules for the given receptor. A) The MOE
340 result, B) The Schrödinger result and C) the DrugOn result.

341 **Figure S3.** The PARN use case benchmark of DrugOn. Top: The 3D alignment
342 of the qualifying molecules for the catalytic site of PARN. On the left is the
343 MOE output while on the right is the DrugOn result. Bottom: The final 3D
344 pharmacophore model for PARN. The MOE output is on the Left while the

DrugOn 3D pharmacophore is on the right. The results are almost identical and have been confirmed *in vitro* by enzymatic biological assays.

REFERENCES:

Arooj M, Sakkiah S, Kim S, Arulalapperumal V, and Lee KW. 2013. A combination of receptor-based pharmacophore modeling & QM techniques for identification of human chymase inhibitors. *PLoS One* 8:e63030.

Balatsos N, Vlachakis D, Chatzigeorgiou V, Manta S, Komiotis D, Vlassi M, Stathopoulos C. 2012 Kinetic and *in silico* analysis of the slow-binding inhibition of human poly (A)-specific ribonuclease (PARN) by novel nucleoside analogues. Biochimie 94 (1), 214-221

Chen M, Svicher V, Artese A, Costa G, Alteri C, Ortuso F, Parrotta L, Liu Y, Liu C, Perno CF, Alcaro S, and Zhang J. 2013. Detecting and understanding genetic and structural features in HIV-1 B subtype V3 underlying HIV-1 co-receptor usage. *Bioinformatics* 29:451-460.

Dalkas GA, Vlachakis D, Tsagkrasoulis D, Kastania A, and Kossida S. 2013. State-of-the-art technology in modern computer-aided drug design. *Brief Bioinform* 14:745-752.

DeLano WL. 2002. The PyMOL Molecular Graphics System DeLano Scientific. San Carlos, CA, USA.

Dixon, S.L.; Smondyrev, A.M.; Knoll, E.H.; Rao, S.N.; Shaw, D.E.; Friesner, R.A. 2006a "PHASE: A New Engine for Pharmacophore Perception, 3D QSAR Model Development, and 3D Database Screening. 1. Methodology and Preliminary Results," *J. Comput. Aided Mol. Des. 20*, 647-671

Dixon, S.L.; Smondyrev, A.M.; Rao, S.N. 2006b "PHASE: A Novel Approach to Pharmacophore Modeling and 3D Database Searching," *Chem. Biol. Drug Des. 67*, 370-372

Dolinsky TJ, Czodrowski P, Li H, Nielsen JE, Jensen JH, Klebe G, and Baker NA. 2007. PDB2PQR: expanding and upgrading automated preparation of biomolecular structures for molecular simulations. *Nucleic Acids Res* 35:W522-525.

Dolinsky TJ, Nielsen JE, McCammon JA, and Baker NA. 2004. PDB2PQR: an automated pipeline for the setup of Poisson-Boltzmann electrostatics calculations. *Nucleic Acids Res* 32:W665-667.

Donsky E, and Wolfson HJ. 2011. PepCrawler: a fast RRT-based algorithm for high-resolution refinement and binding affinity estimation of peptide inhibitors. *Bioinformatics* 27:2836-2842.

Ehrlich P. 1909. Ueber den jetzigen Stand der Chemotherapie. *Ber Dtsch Chem Ges* 42:17-47.

Faulon JL, Misra M, Martin S, Sale K, and Sapra R. 2008. Genome scale enzyme-metabolite and drug-target interaction predictions using the signature molecular descriptor. *Bioinformatics* 24:225-233.

Fei J, Zhou L, Liu T, and Tang XY. 2013. Pharmacophore modeling, virtual screening, and molecular docking studies for discovery of novel Akt2 inhibitors. *Int J Med Sci* 10:265-275.

Floris M, Masciocchi J, Fanton M, and Moro S. 2011. Swimming into peptidomimetic chemical space using pepMMsMIMIC. *Nucleic Acids Res* 39:W261-269.

Frommel C, Gille C, Goede A, Gropl C, Hougardy S, Nierhoff T, Preissner R, and Thimm M. 2003. Accelerating screening of 3D protein data with a graph theoretical approach. *Bioinformatics* 19:2442-2447.

Guner OF. 2000. *Pharmacophore Perception, Development, and Use in Drug Design*: Intl Univ Line; 1 edition.

Guner OF. 2002. History and evolution of the pharmacophore concept in computer-aided drug design. *Curr Top Med Chem* 2:1321-1332.

397   Koes DR, and Camacho CJ. 2011. Pharmer: efficient and exact pharmacophore
398   search. *J Chem Inf Model* 51:1307-1314.
399   Korb O, Monecke P, Hessler G, Stutzle T, and Exner TE. 2010. pharmACOphore:
400   multiple flexible ligand alignment based on ant colony optimization. *J Chem
401   Inf Model* 50:1669-1681.
402   Loukatou S, Papageorgiou L, Fakourelis P, Filntisi A, Polychronidou E, Bassis I,
403   Megalooikonomou V, Makałowski W, Vlachakis D, and Kossida S. 2014.
404   Molecular dynamics simulations through GPU video games technologies.
405   *Journal of Molecular Biochemistry* 3.
406   MOE v. 2010. C.C.G. *1010 Sherbrooke St West, Suite 910, Montreal, Canada, H3A
407   2R*.
408   Niu M, Dong F, Tang S, Fida G, Qin J, Qiu J, Liu K, Gao W, and Gu Y. 2013.
409   Pharmacophore modeling and virtual screening for the discovery of new type
410   4 cAMP phosphodiesterase (PDE4) inhibitors. *PLoS One* 8:e82360.
411   Ortuso F, Langer T, and Alcaro S. 2006. GBPM: GRID-based pharmacophore model:
412   concept and application studies to protein-protein recognition. *Bioinformatics*
413   22:1449-1455.
414   Pires DE, Ascher DB, and Blundell TL. 2014. mCSM: predicting the effects of
415   mutations in proteins using graph-based signatures. *Bioinformatics* 30:335-
416   342.
417   Pronk S, Pall S, Schulz R, Larsson P, Bjelkmar P, Apostolov R, Shirts MR, Smith JC,
418   Kasson PM, van der Spoel D, Hess B, and Lindahl E. 2013. GROMACS 4.5: a
419   high-throughput and highly parallel open source molecular simulation toolkit.
420   *Bioinformatics* 29:845-854.
421   Suresh N, and Vasanthi NS. 2010. Pharmacophore Modeling and Virtual Screening
422   Studies to Design Potential Protein Tyrosine Phosphatase 1B Inhibitors as New
423   Leads. *Journal of Proteomics & Bioinformatics* 3:20-28.
424   Tosco P, and Balle T. 2011. Open3DQSAR: a new open-source software aimed at
425   high-throughput chemometric analysis of molecular interaction fields. *J Mol
426   Model* 17:201-208.
427   Vlachakis D, Argiro A, and Kossida S. 2013a. An update on virology and emerging
428   viral epidemics. *Journal Molecular Biochemistry* 2:80-84.
429   Vlachakis D, Bencurova E, Papangelopoulos N, and Kossida S. 2014. Current State-of-
430   the-Art Molecular Dynamics Methods and Applications. *Adv Protein Chem
431   Struct Biol* 94:269-313.
432   Vlachakis D, Karozou A, and Kossida S. 2013b. 3D Molecular Modelling Study of the
433   H7N9 RNA-Dependent RNA Polymerase as an Emerging Pharmacological
434   Target. *Influenza Res Treat* 2013:645348.
435   Vlachakis D, Kontopoulos DG, and Kossida S. 2013c. Space constrained homology
436   modelling: the paradigm of the RNA-dependent RNA polymerase of dengue
437   (type II) virus. *Comput Math Methods Med* 2013:108910.
438   Vlachakis D, Koumandou VL, and Kossida S. 2013d. A holistic evolutionary and
439   structural study of flaviviridae provides insights into the function and
440   inhibition of HCV helicase. *PeerJ* 1:e74.
441   Vlachakis D, and Kossida S. 2013e. Molecular modeling and pharmacophore
442   elucidation study of the Classical Swine Fever virus helicase as a promising
443   pharmacological target. *PeerJ* 1:e85.
444   Vlachakis D, Pavlopoulou A, Tsiliki G, Komiotis D, Stathopoulos C, Balatsos NA, and
445   Kossida S. 2012a. An integrated in silico approach to design specific inhibitors
446   targeting human poly(a)-specific ribonuclease. *PLoS One* 7:e51113.
447   Vlachakis D, Tsagrasoulis D, Megalooikonomou V, and Kossida S. 2013f. Introducing
448   Drugster: a comprehensive and fully integrated drug design, lead and
449   structure optimization toolkit. *Bioinformatics* 29:126-128.
450   Vlachakis D, Tsaniras SC, Feidakis C, and Kossida S. 2013g. Molecular modelling
451   study of the 3D structure of the biglycan core protein, using homology
452   modelling techniques. *Journal Molecular Biochemistry* 2:85-93.

453 Vlachakis D, Tsaniras SC, and Kossida S. 2012b. Current viral infections and
454   epidemics of flaviviridae; lots of grief but also some hope. *Journal Molecular*
455   *Biochemistry* 3.
456 Vlachakis D, Tsiliki G, and Kossida S. 2013h 3D Molecular Modelling of the Helicase
457   Enzyme of the Endemic, Zoonotic Greek Goat Encephalitis Virus. *Springer*
458   383:165-171.
459 Vlachakis D, Tsiliki G, Pavlopoulou A, Roubelakis MG, Tsaniras SC, and Kossida S.
460   2013i. Antiviral Stratagems Against HIV-1 Using RNA Interference (RNAi)
461   Technology. *Evol Bioinform Online* 9:203-213.
462 Wallach I, and Lilien RH. 2009. Prediction of sub-cavity binding preferences using an
463   adaptive physicochemical structure representation. *Bioinformatics* 25:i296-
464   304.
465 Wang R, Gao Y, and Lal L. 2000. LigBuilder: a multi-purpuse program for structure-
466   based drug design. *Journal of Molecular Modeling* 6:498-516.
467 Wermuth CG. 1998. Glossary of terms used in medicinal chemistry (IUPAC
468   recommendations 1997). *Annu Rep Med Chem* 33:385-395.
469 Wolber G, Dornhofer AA, and Langer T. 2006. Efficient overlay of small organic
470   molecules using 3D pharmacophores. *J Comput Aided Mol Des* 20:773-788.
471 Yang SY. 2010. Pharmacophore modeling and applications in drug discovery:
472   challenges and recent advances. *Drug Discov Today* 15:444-450.
473 Yuan Y, Pei J, and Lai L. 2011. LigBuilder 2: a practical de novo drug design
474   approach. *J Chem Inf Model* 51:1083-1091.
475 Zhang M, White RA, Wang L, Goldman R, Kavraki L, and Hassett B. 2005. Improving
476   conformational searches by geometric screening. *Bioinformatics* 21:624-630.

1

Figure 1

The main window of the DrugOn platform.

2

Figure 2

The main window of the DrugOn Pro platform.